Prospective Grant of Exclusive License: Antitumor Macrocyclic Lactones, Compositions and Methods of Use

Riepilogo

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in International Patent Application PCT/US98/15011, all related foreign and domestic patents and patent applications, entitled "Antitumor Macrocyclic Lactones, Compositions and Methods of Use" (DHHS Ref. No. E-244-1997/0), and in International Patent Application PCT/US00/05582, all related foreign and domestic patents and patent applications, entitled "Vacuolar-Type (H + )-ATPase Inhibiting Compounds, Compositions, And Use Thereof " (DHHS Ref. No. E-244-1997/3), to Reata Discovery, Inc., located in Dallas, TX. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide and the field of use may be limited to human therapeutics for the treatment of cancer.